Virtual Medical Academy
AR
  • About
  • Education
  • Library
  • MEMBERSHIP
  • Business
  • Blog
  • login
  • Register Now
login

Register
Now

Log in

Viewing 24 results
  • ALL
  • Research & Ethics
  • Soft Skills
  • Medicine & Surgery
    • Pediatric
    • Internal Medicine
    • Neurology
    • ICU
    • General Surgery
    • ENT
    • Dermatology
    • Emergency
    • Family Medicine
    • OB & GYN
    • Psychiatry
    • General
    • Orthopedics
    • Radiology
    • Oncology
    • Diabetes
    • Rheumatology
    • Public Health
  • Allied Medical Sciences
    • MLT
    • Respiratory therapy
    • Physical therapy
    • Rehabilitation
  • Nursing
  • Pharmacy
  • Health Informatics
  • Health administration
  • Medical Education
  • Dentistry
  • E-Nutrition Hub

You are viewing the category of Dermatology

Dermatology
Ebglyss Monthly Maintenance Dosing.Simply No lab monitoring , No boxed warning & No dose adjustment

Ebglyss Monthly Maintenance Dosing.Simply No lab monitoring , No boxed warning & No dose adjustment

By :
Prof.Vimal Prajapati
Dermatology
Discover the 2 Years effcacy data of Ebglyss in Atopic Dermatitis – ADjoin Trial Highlights

Discover the 2 Years effcacy data of Ebglyss in Atopic Dermatitis – ADjoin Trial Highlights

By :
Prof.Vimal Prajapati
Dermatology
Ebglyss Clinical Trials: Proven Efficacy in Atopic Dermatitis – Advocate 1 and 2 Insights

Ebglyss Clinical Trials: Proven Efficacy in Atopic Dermatitis – Advocate 1 and 2 Insights

By :
Prof.Vimal Prajapati
Dermatology
Ebglyss features a unique mechanism of action—binding to interleukin-13 with high affinity and a slow dissociation rate

Ebglyss features a unique mechanism of action—binding to interleukin-13 with high affinity and a slow dissociation rate

By :
Prof.Vimal Prajapati
Dermatology
Unmet Medical Needs in Atopic Dermatitis: Ebglyss – A New IL-13 inhibitor Biologic for Moderate to Severe AD

Unmet Medical Needs in Atopic Dermatitis: Ebglyss – A New IL-13 inhibitor Biologic for Moderate to Severe AD

By :
Prof.Vimal Prajapati
Dermatology
Empowering Atopic Dermatitis Management with Ebglyss Start Strong, Last Long, Maintain Monthly

Empowering Atopic Dermatitis Management with Ebglyss Start Strong, Last Long, Maintain Monthly

By :
Prof.Vimal Prajapati
Dermatology
How Ebglyss (Lebrikizumab) Works in Atopic Dermatitis

How Ebglyss (Lebrikizumab) Works in Atopic Dermatitis

By :
Lilly Saudi Arabia
Dermatology
Ebglyss Approved in Saudi Arabia – A New Hope for Moderate to Severe Atopic Dermatitis

Ebglyss Approved in Saudi Arabia – A New Hope for Moderate to Severe Atopic Dermatitis

By :
Lilly Saudi Arabia
Dermatology
Assessing Subjective Burden in Patients with Atopic Dermatitis

Assessing Subjective Burden in Patients with Atopic Dermatitis

By :
Pro.Jonathan & Prof.Melinda
Dermatology
Assessing Clinical Severity in Patients with Atopic Dermatitis

Assessing Clinical Severity in Patients with Atopic Dermatitis

By :
Pro.Jonathan & Prof.Melinda
Dermatology
Assessing lack of treatment response in patients with Atopic Dermatitis

Assessing lack of treatment response in patients with Atopic Dermatitis

By :
Pro.Jonathan & Prof.Melinda
Dermatology
Targeting IL-13: Does It Scratch the Itch in Atopic Dermatitis?

Targeting IL-13: Does It Scratch the Itch in Atopic Dermatitis?

By :
Dr. Sarina Elmariah
Show More

Call Center          920008161

[email protected]

About Us
Support
Technical Requirements
VMA Team
Partner
© VMA 2025
  • Company Detail
  • Term&Condition
  • Privacy Policy
  • Careers
  • Payment Method
Powered By Virtual Medical Academy